株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

脊髄損傷:パイプライン分析

Spinal Cord Injury - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 229793
出版日 ページ情報 英文 192 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
脊髄損傷:パイプライン分析 Spinal Cord Injury - Pipeline Review, H2 2016
出版日: 2016年11月23日 ページ情報: 英文 192 Pages
概要

脊髄損傷は、脊髄が身体的外傷を受けたものであると定義され、運動機能や感覚が失われたり障害が残ったりします。通常、身体的外傷や疾患(横断性脊髄炎、ポリオ、脊椎破裂、フリードライヒ運動失調症)によって引き起こされます。 事故後に現れるこの疾患の緊急的な兆候は、背中に激しい痛みが起こる、首や頭、あるいは背中に圧迫感がある、体のどこかの力が抜けたり、感覚が無くなる、手、指、足、つま先がしびれたり感覚が無くなる、膀胱や腸のコントロールがきかなくなる、バランスを取り歩くのが困難になる、事故後に呼吸障害が起きる、首や背中が奇妙な形になったりねじれたりします。

当レポートでは、脊髄損傷の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

脊髄損傷 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • Acorda Therapeutics, Inc.
  • Asterias Biotherapeutics, Inc.
  • Asubio Pharma Co., Ltd.
  • Athersys, Inc.
  • BioArctic Neuroscience AB
  • BioAxone BioSciences, Inc.
  • FirstString Research, Inc.
  • Genervon Biopharmaceuticals, LLC
  • Histocell S.L.
  • Kadimastem Ltd. .
  • Kringle Pharma, Inc.
  • Lipopharma Therapeutics SL
  • Lpath, Inc.
  • MandalMed, Inc.
  • Mapreg S.A.S.
  • Neuralstem, Inc.
  • Neuronax SAS
  • New World Laboratories, Inc.
  • Omeros Corporation
  • PharmatrophiX, Inc.
  • Pharmicell Co., Ltd.
  • Protagenic Therapeutics Inc.
  • Q Therapeutics, Inc.
  • Remedy Pharmaceuticals, Inc.
  • RespireRx Pharmaceuticals Inc.
  • RhinoCyte, Inc.
  • SanBio, Inc.
  • Sirnaomics, Inc.
  • StemCells, Inc.
  • Stemedica Cell Technologies, Inc.
  • TissueGene, Inc.
  • Tumorend, LLC
  • Vertex Pharmaceuticals Incorporated
  • Vicore Pharma AB

治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8703IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Spinal Cord Injury - Pipeline Review, H2 2016, provides an overview of the Spinal Cord Injury (Central Nervous System) pipeline landscape.

Spinal cord injury (SCI) is defined as damage or trauma caused to the spinal cord. SCI can lead to loss or impaired function resulting in reduced mobility or feeling. It is usually caused by trauma, transverse myelitis, polio, spina bifida or Friedreich's ataxia. Signs and symptoms of spinal cord injury include extreme back pain or pressure in the neck, head or back, paralysis in any part of the body, numbness, tingling or loss of sensation in the hands, fingers, feet or toes, loss of bladder or bowel control, difficulty in walking and impaired breathing after injury.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Spinal Cord Injury - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Spinal Cord Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Spinal Cord Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Spinal Cord Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 10, 7, 23 and 6 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 15 and 2 molecules, respectively.Spinal Cord Injury.

Spinal Cord Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Spinal Cord Injury (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Spinal Cord Injury (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Spinal Cord Injury (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Spinal Cord Injury (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Spinal Cord Injury (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Spinal Cord Injury (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Spinal Cord Injury (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • List of Tables 5
  • List of Figures 6
  • Introduction 7
  • Global Markets Direct Report Coverage 7
  • Spinal Cord Injury Overview 8
  • Therapeutics Development 9
  • Pipeline Products for Spinal Cord Injury - Overview 9
  • Pipeline Products for Spinal Cord Injury - Comparative Analysis 10
  • Spinal Cord Injury - Therapeutics under Development by Companies 11
  • Spinal Cord Injury - Therapeutics under Investigation by Universities/Institutes 14
  • Spinal Cord Injury - Pipeline Products Glance 15
  • Late Stage Products 15
  • Clinical Stage Products 16
  • Early Stage Products 17
  • Spinal Cord Injury - Products under Development by Companies 18
  • Spinal Cord Injury - Products under Investigation by Universities/Institutes 21
  • Spinal Cord Injury - Companies Involved in Therapeutics Development 22
  • AbbVie Inc 22
  • Acorda Therapeutics Inc 23
  • Asterias Biotherapeutics, Inc. 24
  • Asubio Pharma Co Ltd 25
  • Athersys Inc 26
  • BioArctic Neuroscience AB 27
  • BioAxone BioSciences Inc 28
  • Genervon Biopharmaceuticals LLC 29
  • Histocell SL 30
  • Kadimastem Ltd 31
  • Kringle Pharma Inc 32
  • Lpath Inc 33
  • MandalMed Inc 34
  • Mapreg SAS 35
  • Medgenics Inc 36
  • Neuralstem Inc 37
  • Neuronax SAS 38
  • New World Laboratories Inc 39
  • Omeros Corp 40
  • PharmatrophiX, Inc. 41
  • Pharmicell Co Ltd 42
  • Protagenic Therapeutics Inc. 43
  • Q Therapeutics Inc 44
  • Remedy Pharmaceuticals Inc 45
  • RespireRx Pharmaceuticals Inc 46
  • SanBio Inc 47
  • Stemedica Cell Technologies Inc 48
  • TissueGene Inc 49
  • TRB Chemedica International SA 50
  • Tumorend LLC 51
  • Vertex Pharmaceuticals Inc 52
  • Vicore Pharma AB 53
  • Spinal Cord Injury - Therapeutics Assessment 54
  • Assessment by Monotherapy Products 54
  • Assessment by Combination Products 55
  • Assessment by Target 56
  • Assessment by Mechanism of Action 59
  • Assessment by Route of Administration 62
  • Assessment by Molecule Type 64
  • Drug Profiles 66
  • (buspirone + carbidopa + levodopa) - Drug Profile 66
  • ABT-555 - Drug Profile 67
  • AP-325 - Drug Profile 68
  • APO-1 - Drug Profile 69
  • ASTOPC-1 - Drug Profile 70
  • AX-007 - Drug Profile 76
  • BA-277 - Drug Profile 77
  • BA-434 - Drug Profile 78
  • C-21 - Drug Profile 79
  • Cell Therapy for Spinal Cord Injury - Drug Profile 81
  • Cell Therapy to Activate hNT-3 for Spinal Cord and Traumatic Brain Injury - Drug Profile 82
  • Cellgram-SCI - Drug Profile 83
  • CHEC-7 - Drug Profile 84
  • CHEC-9 - Drug Profile 85
  • chondroitinase ABC nanosphere - Drug Profile 86
  • CLR-01 - Drug Profile 87
  • CM-101 - Drug Profile 88
  • CX-717 - Drug Profile 89
  • Drug for Spinal Cord Injury - Drug Profile 91
  • FAB-117HC - Drug Profile 92
  • Gene Therapy for Spinal Cord Injury and Neurodegenerative Diseases - Drug Profile 93
  • glyburide - Drug Profile 94
  • GM-603 - Drug Profile 97
  • HBN-1 - Drug Profile 98
  • ICCN-100 - Drug Profile 99
  • IMS-001 - Drug Profile 100
  • IMS-002 - Drug Profile 101
  • JM-4 - Drug Profile 102
  • KP-100IT - Drug Profile 103
  • LM11A-31BHS - Drug Profile 105
  • LPA-181 - Drug Profile 107
  • Lpathomab - Drug Profile 108
  • MAP-4343 - Drug Profile 111
  • Neu-2000 - Drug Profile 112
  • NeuroRelease SCI - Drug Profile 113
  • neurovitas - Drug Profile 114
  • NOVO-117 - Drug Profile 115
  • NSI-566 - Drug Profile 116
  • NWL-53 - Drug Profile 124
  • NX-210 - Drug Profile 125
  • Oligonucleotide for Central Nervous System and Metabolic Disorders - Drug Profile 126
  • PF-05285401 - Drug Profile 127
  • porcine GM1 ganglioside - Drug Profile 137
  • PT-00114 - Drug Profile 138
  • Q-Cells - Drug Profile 139
  • Recombinant Chondroitinase to Inhibit Chondroitin Sulfate Proteoglycan for Spinal Cord Injury and Brain Injury - Drug Profile 141
  • Recombinant Protein to Antagonize EPHA4 for ALS, Acute Spinal Cord Injury and Ischemia Reperfusion Injury - Drug Profile 142
  • SB-618 - Drug Profile 143
  • SB-623 - Drug Profile 144
  • SC-0806 - Drug Profile 148
  • Small Molecule to Antagonize GPR17 for Central Nervous System Disorders - Drug Profile 149
  • Small Molecules for Spinal Cord Injury - Drug Profile 150
  • Small Molecules to Block Voltage-Gated Potassium Channel for Spinal Cord Injury and Multiple Sclerosis - Drug Profile 151
  • Stem Cell Therapy for Central Nervous System Disorders - Drug Profile 152
  • Stem Cell Therapy for CNS Disorders - Drug Profile 153
  • Stem Cell Therapy for Neurodegenerative Diseases - Drug Profile 154
  • Stem Cell Therapy for Spinal Cord Injury - Drug Profile 156
  • Stem Cell Therapy for Spinal Cord Injury - Drug Profile 157
  • Stem Cell Therapy for Spinal Cord Injury - Drug Profile 158
  • SUN-13837 - Drug Profile 159
  • Synthetic Peptide to Antagonize PTPRS for Spinal Cord Injury - Drug Profile 160
  • Synthetic Peptides to Activate SDF-1 Alpha for CNS Disorders and Infectious Disease - Drug Profile 161
  • TG-N - Drug Profile 162
  • UH-0113 - Drug Profile 163
  • UH-0213 - Drug Profile 164
  • VX-210 - Drug Profile 165
  • Spinal Cord Injury - Dormant Projects 168
  • Spinal Cord Injury - Discontinued Products 174
  • Spinal Cord Injury - Product Development Milestones 175
  • Featured News & Press Releases 175
  • Appendix 186
  • Methodology 186
  • Coverage 186
  • Secondary Research 186
  • Primary Research 186
  • Expert Panel Validation 186
  • Contact Us 186
  • Disclaimer 187

List of Tables

  • Number of Products under Development for Spinal Cord Injury, H2 2016 14
  • Number of Products under Development for Spinal Cord Injury - Comparative Analysis, H2 2016 15
  • Number of Products under Development by Companies, H2 2016 16
  • Number of Products under Development by Companies, H2 2016 (Contd..1) 17
  • Number of Products under Development by Companies, H2 2016 (Contd..2) 18
  • Number of Products under Investigation by Universities/Institutes, H2 2016 19
  • Comparative Analysis by Late Stage Development, H2 2016 20
  • Comparative Analysis by Clinical Stage Development, H2 2016 21
  • Comparative Analysis by Early Stage Development, H2 2016 22
  • Products under Development by Companies, H2 2016 23
  • Products under Development by Companies, H2 2016 (Contd..1) 24
  • Products under Development by Companies, H2 2016 (Contd..2) 25
  • Products under Investigation by Universities/Institutes, H2 2016 26
  • Spinal Cord Injury - Pipeline by AbbVie Inc, H2 2016 27
  • Spinal Cord Injury - Pipeline by Acorda Therapeutics Inc, H2 2016 28
  • Spinal Cord Injury - Pipeline by Asterias Biotherapeutics, Inc., H2 2016 29
  • Spinal Cord Injury - Pipeline by Asubio Pharma Co Ltd, H2 2016 30
  • Spinal Cord Injury - Pipeline by Athersys Inc, H2 2016 31
  • Spinal Cord Injury - Pipeline by BioArctic Neuroscience AB, H2 2016 32
  • Spinal Cord Injury - Pipeline by BioAxone BioSciences Inc, H2 2016 33
  • Spinal Cord Injury - Pipeline by Genervon Biopharmaceuticals LLC, H2 2016 34
  • Spinal Cord Injury - Pipeline by Histocell SL, H2 2016 35
  • Spinal Cord Injury - Pipeline by Kadimastem Ltd, H2 2016 36
  • Spinal Cord Injury - Pipeline by Kringle Pharma Inc, H2 2016 37
  • Spinal Cord Injury - Pipeline by Lpath Inc, H2 2016 38
  • Spinal Cord Injury - Pipeline by MandalMed Inc, H2 2016 39
  • Spinal Cord Injury - Pipeline by Mapreg SAS, H2 2016 40
  • Spinal Cord Injury - Pipeline by Medgenics Inc, H2 2016 41
  • Spinal Cord Injury - Pipeline by Neuralstem Inc, H2 2016 42
  • Spinal Cord Injury - Pipeline by Neuronax SAS, H2 2016 43
  • Spinal Cord Injury - Pipeline by New World Laboratories Inc, H2 2016 44
  • Spinal Cord Injury - Pipeline by Omeros Corp, H2 2016 45
  • Spinal Cord Injury - Pipeline by PharmatrophiX, Inc., H2 2016 46
  • Spinal Cord Injury - Pipeline by Pharmicell Co Ltd, H2 2016 47
  • Spinal Cord Injury - Pipeline by Protagenic Therapeutics Inc., H2 2016 48
  • Spinal Cord Injury - Pipeline by Q Therapeutics Inc, H2 2016 49
  • Spinal Cord Injury - Pipeline by Remedy Pharmaceuticals Inc, H2 2016 50
  • Spinal Cord Injury - Pipeline by RespireRx Pharmaceuticals Inc, H2 2016 51
  • Spinal Cord Injury - Pipeline by SanBio Inc, H2 2016 52
  • Spinal Cord Injury - Pipeline by Stemedica Cell Technologies Inc, H2 2016 53
  • Spinal Cord Injury - Pipeline by TissueGene Inc, H2 2016 54
  • Spinal Cord Injury - Pipeline by TRB Chemedica International SA, H2 2016 55
  • Spinal Cord Injury - Pipeline by Tumorend LLC, H2 2016 56
  • Spinal Cord Injury - Pipeline by Vertex Pharmaceuticals Inc, H2 2016 57
  • Spinal Cord Injury - Pipeline by Vicore Pharma AB, H2 2016 58
  • Assessment by Monotherapy Products, H2 2016 59
  • Assessment by Combination Products, H2 2016 60
  • Number of Products by Stage and Target, H2 2016 62
  • Number of Products by Stage and Mechanism of Action, H2 2016 65
  • Number of Products by Stage and Route of Administration, H2 2016 68
  • Number of Products by Stage and Molecule Type, H2 2016 70
  • Spinal Cord Injury - Dormant Projects, H2 2016 173
  • Spinal Cord Injury - Dormant Projects (Contd..1), H2 2016 174
  • Spinal Cord Injury - Dormant Projects (Contd..2), H2 2016 175
  • Spinal Cord Injury - Dormant Projects (Contd..3), H2 2016 176
  • Spinal Cord Injury - Dormant Projects (Contd..4), H2 2016 177
  • Spinal Cord Injury - Dormant Projects (Contd..5), H2 2016 178
  • Spinal Cord Injury - Discontinued Products, H2 2016 179

List of Figures

  • Number of Products under Development for Spinal Cord Injury, H2 2016 14
  • Number of Products under Development for Spinal Cord Injury - Comparative Analysis, H2 2016 15
  • Number of Products under Development by Companies, H2 2016 16
  • Number of Products under Investigation by Universities/Institutes, H2 2016 19
  • Comparative Analysis by Clinical Stage Development, H2 2016 21
  • Comparative Analysis by Early Stage Products, H2 2016 22
  • Assessment by Monotherapy Products, H2 2016 59
  • Number of Products by Top 10 Targets, H2 2016 61
  • Number of Products by Stage and Top 10 Targets, H2 2016 61
  • Number of Products by Top 10 Mechanism of Actions, H2 2016 64
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 64
  • Number of Products by Routes of Administration, H2 2016 67
  • Number of Products by Stage and Routes of Administration, H2 2016 67
  • Number of Products by Top 10 Molecule Types, H2 2016 69
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016 69
Back to Top